DeepMed Research

Gustave Roussy, Cancer Campus, Grand Paris

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Neurocognitive Risks in Children With Solid Tumors

Recruiting

Conditions: Solid Tumor in Children

Interventions: Other: The WISC-IV
Other: The CMS (CHILD MEMORY SCALE)
Other: CONNERS
Other: BRIEF
Other: PEDS-QL
Other: State Trait Anxiety Inventory
Other: Child Depression Inventory

First Posted Date: 2018-08-01

Last Posted Date: 2024-12-13

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 1000

Registration Number: NCT03609112

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in Non-Small Cell Lung Cancer (NSCLC): Pilot Study

Not Applicable

Conditions: NSCLC

Interventions: Diagnostic Test: PET-MRI

First Posted Date: 2018-07-30

Last Posted Date: 2019-01-04

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 20

Registration Number: NCT03606070

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Study of Coronary Calcium Score as a Marker of Post-radiation Vascular Dysplasia in Adults Treated During Childhood for Cancer With Mediastinal Irradiation

Not Applicable

Recruiting

Conditions: Childhood Cancer

Interventions: Other: Coronal calcium score measurement

First Posted Date: 2018-07-27

Last Posted Date: 2024-05-29

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 500

Registration Number: NCT03604627

Locations: 🇫🇷
Hôpital Bichat, Paris, France
🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
🇫🇷
Hôpital Trousseau, Paris, France

Evaluation of HPV OncoTect ™ for the Etiological Diagnosis of HPV-induced Oropharyngeal Cancers

Not Applicable

Conditions: Oropharyngeal Cancer

Interventions: Diagnostic Test: HPV OncoTect™

First Posted Date: 2018-07-27

Last Posted Date: 2018-07-27

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 40

Registration Number: NCT03604588

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer

Phase 1

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Pembrolizumab
Drug: pegylated liposomal doxorubicin (PLD)
Drug: Bevacizumab

First Posted Date: 2018-07-23

Last Posted Date: 2024-10-18

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 47

Registration Number: NCT03596281

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France

ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer

Phase 3

Recruiting

Conditions: Thyroid Cancer

Interventions: Procedure: total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection
Procedure: total thyroidectomy alone without neck dissection

First Posted Date: 2018-06-26

Last Posted Date: 2024-05-16

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 1000

Registration Number: NCT03570021

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma

Phase 3

Active, not recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Other: injected CT-scan
Procedure: Nasofibroscopy
Other: whole body PET-CT
Other: Low Dose Chest CTscan
Procedure: Lugol upper gastrointestinal endoscopy
Procedure: Biopsy

First Posted Date: 2018-05-08

Last Posted Date: 2024-03-26

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 197

Registration Number: NCT03519048

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2018-01-23

Last Posted Date: 2025-05-08

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 140

Registration Number: NCT03406247

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Two Chemotherapy Regimens Plus or Minus Bevacizumab

Phase 2

Active, not recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: LV5FU2
Drug: Capecitabine
Drug: Streptozocin
Drug: Temozolomide
Drug: Bevacizumab

First Posted Date: 2017-11-22

Last Posted Date: 2024-05-08

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 140

Registration Number: NCT03351296

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
🇫🇷
CHU de Caen, Caen, Calvados, France
🇫🇷
ICM Val d'Aurelle, Montpellier, Hérault, France

and more 16 locations

A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer

Phase 2

Completed

Conditions: Metastatic Castrate-resistant Prostate (CRPC) Cancer

Interventions: Drug: Enzalutamide
Drug: ODM-201

First Posted Date: 2017-10-19

Last Posted Date: 2025-04-17

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 250

Registration Number: NCT03314324

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy